Summary Varian Medical Systems Inc (VMS) designs, manufactures, and sells medical devices, associated hardware and software, and a broad portfolio of interventional solutions for the treatment of cancer.The company’s major product areas include radiosurgery, radiotherapy, proton therapy, brachytherapy, adaptive therapy, interventional therapy, and software.
The company markets its products to private and government institutions, university research and community hospitals, oncology practices, healthcare agencies, physicians’ offices, radiotherapy centers, and cancer care clinics in North America, Europe, Asia-Pacific, the Middle East, and Africa.It also operates a specialty hospital in India and a cancer center in Sri Lanka.
VMS is headquartered in Palo Alto, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Varian Medical Systems Inc - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
The ablation technology market is projected to reach USD 8.1 Billion by 2026 from USD 5.2 Billion in 2021, at a CAGR of 9.3% during the forecast period. The growing elderly population has also driven the incidence of target conditions and contributed to the demand for effective treatment. However, the reuse and reprocessing of devices in developed...
242 pages •
By Asia Market Information & Development Company
• Aug 2021
China’s demand for Pneumonia Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal Type (Canine, Feline), And Segment Forecasts, 2021 - 2028 U.S. Veterinary Oncology Market Growth & Trends The U.S. veterinary oncology market size is expected...
The global radiotherapy market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period. The growth of this market is primarily driven by the rising burden of target diseases and increasing investments, funds, and grants for the development of novel products. Additionally,...
The global wearable injectors market is projected to reach USD 11.5billion by 2026 from USD 7.2billion in 2021, at a CAGR of 9.9% during the forecast period. Growth in this market is mainly driven by factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various...
Microbiome - Targeted Therapeutics in Immunology - Thematic Research
The microbiome is considered the genetic material of all microorganisms existing in and on the human body.Large resident microbial communities exist in the gastrointestinal (GI) tract, skin, and respiratory tract, and...
“Lysine Specific Demethylase 1 (LSD-1) Inhibitors - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Lysine Specific Demethylase 1 (LSD-1) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics...
216 pages •
By Global Industry Analysts
• Apr 2021
- Global Multiple Myeloma Therapeutics Market to Reach $27.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Multiple Myeloma Therapeutics estimated at US$9.9 Billion in the year 2020, is projected to reach a revised size of US$27.1 Billion by 2027, growing at a CAGR of 15.5% over the analysis...
The global injectables market is estimated to reach US$759.61 billion in 2025, progressing at a CAGR of 10.95%, over the period 2021-2025. Factors such as increasing geriatric population, upsurge in demand for convenient drug delivery, expanding use of biologics, rising healthcare expenditure and surging incidence of cancer cases would drive...
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.